Comparing a new eye drop to cyclosporine for eye allergy in kids
Part of Eyes & vision, Immune system & allergy clinical trials.
This study tests a new eye drop (T1695) against cyclosporine for children with moderate to severe vernal keratoconjunctivitis, a type of eye allergy. It aims to see which treatment works better and is safer for reducing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 4 and 17 years old.
- You have a diagnosis of vernal keratoconjunctivitis (a severe eye allergy) that is graded as moderate to severe (score 3 or 4 on a standard scale) in both eyes.
- You have signed a consent form (or your parent/guardian has for you).
- You do not have any other eye condition or health issue that would make the study unsafe or interfere with the results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tacrolimus eye drops can reduce the symptoms of vernal keratoconjunctivitis (a severe eye allergy) in children aged 5 to 15. If effective, the treatment could provide a new option to control this uncomfortable condition.
This trial tests if adding cyclosporine A to the standard natamycin eye drops can better treat fungal eye infections. It may help people with moderate vision loss from a fungal corneal infection.
This trial tests a new eye drop called diquafosol for people with a severe, active eye allergy called vernal keratoconjunctivitis. It aims to see if the drops can calm the allergy and help heal the surface of the eye.
This study compares two different cyclosporine eye drops to see which one better improves the health of the surface of your eye. One is a newer version (Vevye) and the other is a generic version of Restasis, over 8 weeks of treatment.
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
This trial tests a new eye gel that contains cyclosporine (a medicine that lowers inflammation) to see if it helps with dry eye symptoms. If you have long-lasting dry eye, this study might offer a new treatment option.
Hear when a new Moderate to Severe Vernal Keratoconjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.